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ABSTRACT
Objective Duchenne muscular dystrophy (DMD) is
characterised by progressive muscle weakness. It has
recently been reported that single nucleotide
polymorphisms (SNPs) located in the SPP1 and LTBP4 loci
can account for some of the inter-individual variability
observed in the clinical disease course. The validation of
genetic association in large independent cohorts is a key
process for rare diseases in order to qualify prognostic
biomarkers and stratify patients in clinical trials.
Methods Duchenne patients from five European
neuromuscular centres were included. Information about
age at wheelchair dependence and steroid use was
gathered. Melting curve analysis of PCR fragments or
Sanger sequencing were used to genotype SNP
rs28357094 in the SPP1 gene in 336 patients. The
genotype of SNPs rs2303729, rs1131620, rs1051303
and rs10880 in the LTBP4 locus was determined in 265
patients by mass spectrometry. For both loci, a
multivariate analysis was performed, using genotype/
haplotype, steroid use and cohort as covariates.
Results We show that corticosteroid treatment and the
IAAM haplotype of the LTBP4 gene are significantly
associated with prolonged ambulation in patients with
DMD. There was no significant association between the
SNP rs28357094 in the SPP1 gene and the age of
ambulation loss.
Conclusions This study underlines the importance of
replicating genetic association studies for rare diseases in
large independent cohorts to identify the most robust
associations. We anticipate that genotyping of validated
genetic associations will become important for the design
and interpretation of clinical trials.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is a progres-
sive muscle disease caused by protein truncating
mutations in the DMD gene leading to dystrophin
absence.1 Differences in disease progression, the
reasons for which are largely unknown, have been
described in the past.2 3 It has been hypothesised
that variation in the inflammatory response to
muscle damage could be responsible for the differ-
ences among patients. Evidence for this hypothesis
was recently described in two papers reporting a
relationship between the single nucleotide poly-
morphism (SNP) rs28357094 in the SPP1 gene and
disease severity.4 5 The same SNP was later
reported to influence muscle size in healthy
females.6 It has also been shown that osteopontin,
the SPP1 gene product, has pro-inflammatory
effects and worsens the muscle phenotype of mice
lacking dystrophin.7
Recently an haplotype composed of four non-
synonymous SNPs in the latent transforming
growth factor-β (TGF-β) binding protein 4 (LTBP4)
gene has also been associated with delayed disease
progression in patients with DMD.8 The SNPs
involved are rs2303729, rs1131620, rs1051303
and rs10880 coding for V194I, T787A, T820A
and T1141M amino acids, respectively (SNPs
mapped to Uniprot isoform Q8N2S1-1, also
known as LTBP-4L). Flanigan and co-authors
described the IAAM haplotype to be associated
with prolonged ambulation in patients with DMD.
It has been postulated that the LTBP4 protein car-
rying IAAM amino acids is able to reduce TGF-β
signalling via altered TGF-β binding or release; this
would benefit patients’ muscle regeneration cap-
acity and reduce muscle fibrosis. These results are
in line with previous findings in a mouse model for
γ-sarcoglycanopathy where LTBP4 was reported as
a modifier for muscular dystrophy.9
In the current study, we aimed to validate whether
the SPP1 rs28357094 SNP and LTBP4 IAAM haplo-
types modulate disease progression in a large multi-
centre cohort composed of five independent
subcohorts from four different countries. Two
cohorts were from the UK (Newcastle and London),
one from the Netherlands (Leiden), one from
France (Montpellier) and one from Italy (Ferrara).
The approach took advantage of the resources and
harmonised standard operating procedures devel-
oped in the FP7-funded BIO-NMD consortium.
METHODS
Patients
Patients with a mutation in the DMD gene and
absence of dystrophin in the skeletal muscle were
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included from neuromuscular databases in Leiden (the
Netherlands), Ferrara (Italy), Montpellier (France), Newcastle
and London (UK). The genetic tests used to diagnose the
patients were performed by each laboratory independently,
using standardised assays as per international guidelines.10
Patients were selected giving priority to non-ambulant patients,
thus enabling a more complete description of the disease course
and reduce censoring during the analysis. Patients’ selection was
also based on comparable historical periods to reduce the vari-
ation that could be introduced by different standards of care;
the mean year of birth per cohort is reported in table 1. Age at
follow-up and age at which ambulation was lost (when applic-
able) were documented. Information about corticosteroid use
was noted, as it is known that steroid treatment is able to slow
down disease progression.11 12 We considered corticosteroid-
treated patients, the ones who started treatment at least
2.5 years prior to wheelchair dependence and continued treat-
ment for at least 1 year. These cut-off points were chosen to
ensure timing and duration of steroid treatment which could
indeed impact age of wheelchair dependence. The study was
approved by the local Research Ethics Committee prior to its
start. Written informed consent for anonymised use of patients’
data for scientific purposes was obtained.
SPP1 genotyping
DNA samples from Newcastle, Leiden, London and Ferrara
were amplified by real-time PCR followed by melting curve
analysis using the LightScanner (Idaho Technology Inc, Salt
Lake City, Utah, USA; see online supplementary figure S1A).
PCR reactions were performed in a final volume of 10 mL con-
taining 20 ng of genomic DNA, 1X PCR Buffer (Roche,
Woerden, the Netherlands), 1X LCGreen Plus (Idaho
Technology Inc), 200 mM dNTPs (Life Technologies, Bleiswijk,
the Netherlands), 2 mM MgCl2 (Roche), 0.3 μM forward and
reverse primer (Eurogentec, Maastricht, the Netherlands; see
online supplementary table S1), 0.4 μM low calibrators
(Eurogentec; see online supplementary table S1) and 0.5 U
FastStart PCR Taq DNA Polymerase (Roche). The thermal
profile was as follows: 10 min at 95°C, then 40 cycles of 20 s at
95°C, 30 s at 60°C, 40 s at 72°C and a final step of 5 min at 72°
C. PCR products were denatured at 95°C for 1 min, rapidly
cooled down to room temperature and melted from 50°C to
98°C at a melt ramp rate of 2°C/s. The fluorescence was mea-
sured in real-time with the LightScanner software (Idaho
Technology Inc). Low calibrators were used as internal controls
to improve genotyping by melting.13 Three samples with a
known genotype for rs28357094 (GG, TT and GT), determined
by Sanger sequencing, were used as internal quality controls.
This procedure was developed and performed at the Leiden
University Medical Center (LUMC) in Leiden for all samples
from Newcastle, Leiden, London and Ferrara.
DNA samples from Montpellier were genotyped by Sanger
sequencing in Montpellier (see online supplementary figure
S1B). The sequence of the primers used for amplification is indi-
cated in online supplementary table S1.
LTBP4 genotyping
To assay SNPs rs2303729, rs1131620, rs1051303 and rs10880,
we used the Sequenom MassARRAY platform (Sequenom Inc,
San Diego, California, USA) according to manufacturer’s proto-
cols, except for the PCR cycling protocol, which was performed
as a step-down protocol (see online supplementary methods).
Multiplex genotyping assays were designed using Sequenom
MassARRAY Assay Design Suite, V.1.0 (Sequenom Inc). After a
step-down PCR, a primer extension reaction was performed to
introduce mass differences between alleles. Primer sequences are
indicated in online supplementary table S2. The product was
spotted onto a target chip with 384 patches containing matrix.
Mass differences were detected using the MassARRAY Compact
System (Bruker, Wormer, the Netherlands) by matrix-assisted
laser desorption\ionisation time-of-flight mass spectrometry
(MALDI-TOF). Data were acquired in real time with the
MassARRAY RT software (Sequenom Inc) and genotypes were
assigned using MassARRAY Typer 4.0.22 software (Sequenom
Inc). Quality control was performed by duplicating 38 samples
within and across plates and by the incorporation of control
DNA as positive control and water as negative control.
Statistical analysis
SNPs were tested for Hardy-Weinberg equilibrium using a
goodness-of-fit test. Statistical analysis of the SPP1 SNP was per-
formed employing a multivariate Cox regression analysis using
steroid use, cohort and genotype as covariates. A second regres-
sion analysis was performed including the same covariates as in
the first model but also including an interaction term between
corticosteroid treatment and genotype. Patients who were still
ambulant at the time of analysis were censored. We used a dom-
inant model for the minor G-allele as previously described.4 5
LTBP4 haplotypes were reconstructed using the haplo.stats
package in R. Haplotypes with a frequency below 10% were
grouped together to form a single category. For two individuals
Table 1 Characteristics of the cohorts for the analysis of single
nucleotide polymorphisms (SNPs) in SPP1 and LTBP4 genes
Leiden Ferrara Montpellier Newcastle London
SPP1
Patients 65 43 107 68 53
Wheelchair dependent 47 43 107 45 46
Mean birth year 1993 1989 1989 1995 1995
Steroid use
Yes 27 13 7 34 21
No 38 30 100 34 32
Mean age of ambulation loss in non-ambulant patients (years)
Overall 9.6 10.1 9.5 10.5 10.8
Steroid treated 10.5 11.5 9.8 12.1 11.6
Non-steroid treated 9.2 9.4 9.5 9.7 10.3
SNP frequencies
TT 52.3 65.1 61.7 64.7 62.3
GT/GG 47.7 34.9 38.3 35.3 37.7
LTBP4
Patients 63 43 38 69 52
Wheelchair dependent 46 43 38 46 45
Mean birth year 1993 1989 1987 1995 1995
Steroid use
Yes 27 13 2 34 20
No 36 30 36 35 32
Mean age of ambulation loss in non-ambulant patients (years)
Overall 9.6 10.1 9.5 10.6 10.8
Steroid treated 10.5 11.5 8.6 12.1 11.7
Non-steroid treated 9.1 9.4 9.6 9.8 10.3
Haplotype frequencies
VTTT 52.0 49.3 51.2 47.6 41.9
IAAM 30.6 28.8 29.8 37.4 47.0
Other 17.4 21.9 19.0 15.0 11.1
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haplotype reconstruction was ambiguous and the most likely
configuration was chosen for these individuals. Cox regression
analysis was performed using steroid use, cohort and the LTBP4
haplotype as covariates. Patients who were still ambulant at the
time of analysis were censored. Data were analysed using the
additive as well as recessive model. In the additive model diplo-
types with one copy of the IAAM haplotype were considered
intermediate, while IAAM/IAAM diplotypes were considered
the extreme. Haplotypes with a frequency below 10% were
grouped together for the analysis with the additive model; this
enabled us to work with three haplotypes groups: VTTT, IAAM
and other (table 1). The analysis with the additive model was
performed using VTTT as well as other as reference haplotypes.
The analysis with the recessive model was performed dividing
patients into two groups: IAAM/IAAM diplotypes and other/
other diplotypes. Age at wheelchair dependence was used as
dependent variable in all analyses. This parameter was chosen as
it is a robust measurement of disease severity, and data about
loss of ambulation were available for all cohorts. Statistical ana-
lysis was performed and p values below 0.05 were considered
significant. Analyses were performed using IBM SPSS software
and R V.2.15.3.
RESULTS
SPP1
The SPP1 SNP rs28357094 was genotyped in 336 patients with
DMD (see online supplementary figures S1A,B). Two hundred
and eighty-eight patients were wheelchair dependent (85.7%),
43 patients (12.8%) were censored, among whom 27 carried
the TT genotype, and 16 carried the GT/GG genotype. Five
cases (4 TT and 1 GT/GG) were dropped (1.5%) since they
were censored before the earliest event. The steroid-treated
group consisted of 102 patients (30.4%; table 1).
Corticosteroid-treated patients lost ambulation later compared
to non-treated patients (11.9 vs 9.6 years; p<0.001). There was
no significant deviation from the Hardy Weinberg equilibrium
for the studied SNP. There was no significant effect of the SPP1
genotype on the age of ambulation loss (p=0.73; table 2 and
figure 1A, B), and no significant interaction between genotype
and corticosteroid treatment (p=0.44). A significant effect of
cohort on age at wheelchair dependence was observed. Patients
from Newcastle and London were significantly associated with a
delayed age at ambulation loss compared to patients belonging
to the other cohorts (table 2).
LTBP4
We genotyped SNPs rs2303729, rs1131620, rs1051303 and
rs10880 in 270 patients (for an example of rs10880 see online
supplementary figure S2). The number of patients included in
this part of the study is lower compared to the SPP1 part due to a
different technical set-up. Four samples failed and were
excluded; another was excluded since the genotyping performed
in duplicate was discordant; the other 37 patients in whom geno-
typing was performed in duplicate were all consistent. For two
patients only three SNPs were genotyped and the fourth SNP
was imputed based on the other three SNPs. The final number of
patients considered for the analysis was 265. Two hundred and
eighteen patients were wheelchair dependent (82.3%) and 47
patients (17.7%) were censored. The steroid group consisted of
96 patients (36.2%). There was no significant deviation from the
Hardy Weinberg equilibrium for the studied SNPs. As shown by
the study of Flanigan et al,8 there was a strong linkage disequilib-
rium within the LTBP4 locus, causing all four SNPs to be usually
inherited together. The frequencies of the reconstructed
haplotypes are shown in online supplementary table S3 and were
in concordance with those published. Table 1 shows haplotype
frequencies per cohort, highlighting how the IAAM haplotype
was more frequent in the UK cohorts compared to the other
cohorts. Corticosteroid treatment had a significant protective
role (p<0.001). The IAAM haplotype was associated with a sig-
nificant delay in ambulation loss compared to the VTTT haplo-
type (p=0.046; table 2) and to the other haplotypes (p=0.01;
see online supplementary table S4) using the additive model. The
additive effect of the IAAM haplotype is visible in figure 2A, B
for corticosteroid naïve and also for corticosteroid-treated
patients. The effect of the IAAM haplotype was confirmed using
the recessive model (p=0.01; table 2 and figure 2C). Differences
in age of ambulation loss were also identified among cohorts;
patients from Newcastle, London and Montpellier were signifi-
cantly associated with delayed ambulation loss compared to
patients from Ferrara and Leiden (table 2).
Table 2 Analysis of the effect of steroid use, cohort and genotype
on age at wheelchair dependence
HR* p Value
SPP1†
Steroid use 0.38 <0.001
SPP1 SNP
TT 1.04 0.73
GT/GG 1‡ –
Cohort
London 1.12 0.60
Ferrara 1.72 0.01
Montpellier 1.82 0.002
Leiden 1.8 0.006
Newcastle 1‡ –
LTBP4†
Additive model
Steroid use 0.31 <0.001
LTBP4 haplotype
IAAM 0.8 0.046
VTTT 1‡ –
other 1.16 0.29
Cohort
London 1.16 0.47
Ferrara 1.62 0.03
Montpellier 1.07 0.79
Leiden 1.83 0.005
Newcastle 1‡ –
Recessive model
Steroid use 0.31 <0.001
LTBP4 diplotypes
IAAM/IAAM 1‡ –
other diplotypes 1.3 0.01
Cohort
London 1.18 0.44
Ferrara 1.69 0.02
Montpellier 1.08 0.75
Leiden 1.88 0.003
Newcastle 1‡ –
*HR above 1 point to an earlier loss of ambulation compared to the reference, while
HRs below 1 point to a later loss of ambulation compared to the reference.
†The reported values were obtained using a dominant model for the SPP1 SNP and
additive and recessive models for the LTBP4 haplotype.
‡These conditions were used as reference, therefore their HRs are set at 1.
SNP, single nucleotide polymorphism.
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DISCUSSION
DMD is the most common muscular dystrophy and is charac-
terised by progressive muscle degeneration. Disease course
varies among patients with most of the patients losing ambula-
tion between 6 and 12 years of age. The reason behind the dif-
ferences in disease progression is so far not clear. However,
genetic modifiers in the SPP1 and LTBP4 loci have been pro-
posed to contribute to the observed differences. Pegoraro et al
reported evidence connecting SNP rs28357094, lying upstream
of the SPP1 gene promoter on chromosome 4, to age of wheel-
chair dependence. The authors showed that the TT genotype
was associated with delayed disease progression in a study of
262 patients derived from two independent cohorts (106
patients from Italy and 156 patients from the USA).5 Later on
the same group published a second report in which patients par-
ticipated in a 12- month longitudinal study where the 6 min
walk test and the North Start Ambulatory Assessment were used
as functional outcome measure; the authors were able to show
that patients with the TT genotype progress slower compared to
the other group.4 We genotyped SNP rs28357094 in 336
Figure 1 Survival plots showing the effect of single nucleotide
polymorphism (SNP) rs28357094 (SPP1) for 336 patients with
Duchenne muscular dystrophy (DMD). Survival plots for
corticosteroid-untreated (A) and corticosteroid-treated (B) patients with
DMD. The two survival lines represent patients stratified according to
their SPP1 SNP genotype (blue=TT, green=GT/GG). Censored patients
are indicated by a cross on the lines.
Figure 2 Survival plots showing the effect of the IAAM haplotype
(LTBP4) in 265 patients with Duchenne muscular dystrophy. Survival
plots showing the additive effect of the IAAM haplotype in steroid
naïve (A) and corticosteroid-treated (B) patients. (C) Comparison of
individuals homozygous for the IAAM haplotype with individuals
carrying other diplotypes separated for corticosteroid-treated and
corticosteroid-untreated patients.
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patients from five independent European cohorts and were
unable to replicate the published association between the SNP
and age of ambulation loss. The association was also not signifi-
cant when the interaction between corticosteroid treatment and
genotype was included in the model. The lack of a clear associ-
ation between this SNP and disease progression is in accordance
with a recent publication from Flanigan et al,8 who studied a
US cohort composed of 254 non-ambulatory patients with
DMD. In this study, the authors went further and presented evi-
dence of a new genetic modifier composed of four SNPs located
in the LTBP4 locus. In line with the scope of this paper to repli-
cate known genetic associations in patients with DMD, we also
genotyped these 4 SNPs in 265 patients with DMD.
Interestingly, we identified a significant association between the
LTBP4 haplotype and disease progression. As in the study by
Flanigan et al, prolonged ambulation was associated with the
IAAM haplotype, which is related to decreased TGF-β signal-
ling. TGF-β is known to inhibit differentiation of satellite cells
and increase fibrosis in muscle tissue.14–16 Several studies have
shown that inhibition of TGF-β function decreases the presence
of fibrosis and increases muscle strength in mdx mice.14–18
Reduced TGF-β signalling, as with the IAAM haplotype, could
therefore slow-down disease progression in patients with DMD.
As expected, in the SPP1 and LTBP4 analyses we observed a
strong effect of steroid treatment in delaying disease progression
(p<0.001).11 12 We also observed a significant cohort effect
with patients from the UK and France performing better com-
pared to the other cohorts. This may be due to differences in
the corticosteroid treatment regimen, to differences in the stan-
dards of care, given that the mean age of birth is different
among the cohorts and that standards of care improve rapidly,
or to differences in the definition of wheelchair dependence
among the participating centres. In our study, the definition of
ambulation loss was homogeneous within each centre, but it
was not standardised among centres. It is therefore possible that
part of the significant differences observed among the cohorts is
due to different definitions of wheelchair dependence. This can
be considered a limit of our study and a general limit in multicen-
tre DMD studies where a significant number of patients is
included to have sufficient statistical power. A limitation of our
approach in replicating the published associations is constituted
by the differences in percentage of corticosteroid-treated
patients, which are lower compared to the published studies
(54% in the study by Pegoraro et al, and 57% in the study by
Flanigan et al) and which also greatly vary among the considered
clinical centres (table 1). However, differences in the definition
of steroid users may partly account for the differences in these
percentages as our definition is more conservative compared to
the one of Flanigan et al. Another limitation of our study is the
use of age at loss of ambulation as the sole measure for disease
severity. Although this is one of the most important disease mile-
stones, it is not sensitive to small effects. Indeed disease modifiers
with a small effect could therefore be overlooked. Future studies
should ideally include data about more sensitive measures, such
as differences in motor function measures.
In conclusion, in the present study we confirm the disease
modifying effect of the IAAM haplotype of the LTBP4 gene, but
could not replicate the previously described association between
SNP rs28357094 in the SPP1 gene and disease severity in
patients with DMD. Future trials in DMD should consider the
LTBP4 haplotype before stratification, as it might confound the
clinical trial results. This study underlines the possibilities and
limitations of genetic association studies in rare diseases with
inherently small cohort sizes.
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